Turning down cortisol,
one tissue at a time.

What Sparrow actually does

Steroids are among the most effective medicines ever discovered, and among the most damaging over time. For roughly seventy years the field has lived with that trade-off: the relief of cortisol on one hand, the metabolic toll - high blood sugar, bone loss, weight gain, cardiovascular strain - on the other. Sparrow Pharmaceuticals was founded in 2013 to attack that trade-off directly rather than accept it.

The company develops small-molecule drugs that inhibit 11β-hydroxysteroid dehydrogenase type 1, or HSD-1 - the enzyme that converts inactive cortisone into active cortisol inside tissues like the liver, fat, bone, and brain. Instead of blunting cortisol everywhere in the body, Sparrow's approach quiets it locally, where the excess causes harm, while leaving the adrenal system that the body depends on largely intact.

Its lead drug, clofutriben - known in earlier trials as SPI-62 - is an oral, once-daily pill. In clinical testing it reduced cortisol inside the liver by roughly 90%. That is the whole bet, stated plainly: precision over force.

The patients behind the science

Sparrow's first patients were people with disorders of cortisol excess - endogenous Cushing's syndrome and autonomous cortisol secretion, a milder but far more common form. These are serious, under-served conditions, and clofutriben earned an FDA Orphan Drug Designation in Cushing's syndrome as it moved through Phase 2.

Then the company followed its own science to a much bigger door. Researchers increasingly recognize that elevated cortisol quietly drives disease progression and treatment resistance in a large slice of people with type 2 diabetes - patients whose blood sugar resists standard therapy. That insight reframed Sparrow from a niche endocrinology player into a cardiometabolic company chasing a market measured in millions.

The immediate stakeholders are the clinicians, academic researchers, and regulators who evaluate the drug on its way to those patients. The ultimate customer is the person whose diabetes will not budge - and for whom cortisol, not just insulin, may be the missing lever.

A decade, one enzyme